中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

未开盘 04-01 16:08:31

6.360

+0.470

+7.98%

最高6.450	最低6.000	成交量1.74亿
今开6.040	昨收5.890	日振幅7.64%
总市值1,193亿	流通市值1,193亿	总股本187.61亿
成交额10.89亿	换手率0.93%	流通股本187.61亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":6.36,"timestamp":1775030911003,"preClose":5.89,"halted":0,"volume":173673242,"delay":0,"changeRate":0.07979626485568772,"floatShares":18761000000,"shares":18761000000,"eps":0.14790949470169606,"marketStatus":"未开盘","change":0.47,"latestTime":"04-01 16:08:31","open":6.04,"high":6.45,"low":6,"amount":1089406228,"amplitude":0.076401,"askPrice":6.36,"askSize":220000,"bidPrice":6.35,"bidSize":923000,"shortable":3,"etf":0,"ttmEps":0.14790949470169606,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775093400000},"marketStatusCode":0,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":5.89,"dividendRate":0.015985,"openAndCloseTimeList":[[1775007000000,1775016000000],[1775019600000,1775030400000]],"volumeRatio":1.9992780400661934,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.1465,"impliedVolPercentile":0.0285},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"1117524656","title":"异动解读 | 大手买入推动，中国生物制药盘中大涨7.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=1117524656","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117524656?lang=zh_cn&edition=full","pubTime":"2026-04-01 12:55","pubTimestamp":1775019313,"startTime":"0","endTime":"0","summary":"中国生物制药今日盘中大涨7.98%，引起了市场的广泛关注。消息面上，该股在盘中出现多笔大手买入交易，其中一笔成交量为84.9万股，成交价为6.35港元，涉资约539万港元；另一笔成交量为85.5万股，成交价为6.34港元，涉资约542万港元。这些大额资金流入直接推动了股价的快速上涨。此外，公司近期发布的股份变动月报表显示，其股本结构维持稳定，无重大变动，这为股价的上涨提供了相对稳定的基本面背景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141573802","title":"中国生物制药3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1141573802","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141573802?lang=zh_cn&edition=full","pubTime":"2026-04-01 09:45","pubTimestamp":1775007938,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司于2026年4月1日发布2026年3月股份变动月报表。报告期内，公司注册股本及已发行股份数目未发生调整，整体股本结构保持不变。此外，公司此前因收购杭州赫吉亚生物医药有限公司100%股权所承诺配发及发行14,596,322股股份的安排，暂定于2028年至2029年分批完成，报告期未涉及实际增发动作。本次月报由公司秘书赖娟签署。截至2026年3月底，中国生物制药整体股本维持稳定，无任何新增发行或注销活动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623370774","title":"招银国际：维持中生制药(01177)“买入”评级 降目标价至8.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623370774","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623370774?lang=zh_cn&edition=full","pubTime":"2026-03-31 13:40","pubTimestamp":1774935623,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，维持中生制药“买入”评级，该行基于DCF，将集团目标价从9.4港元下调至8.7港元，以反映对于非BD收入的预期下调。该行预计公司2026至2028年收入分别同比增长13.5%、7.1%、9.2%，经调整归母净利润同比增长5.4%、8.3%、10.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["EWH","01477","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623630318","title":"中国生物制药(01177)完成收购赫吉亚100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2623630318","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623630318?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:05","pubTimestamp":1774861519,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，内容有关收购赫吉亚100%股权(涉及根据一般授权发行代价股份)的股份交易。董事会欣然宣布，买卖协议项下的所有先决条件均已获达成且交割已于2026年3月30日落实。交割后，赫吉亚已成为公司的间接全资附属公司，且赫吉亚的财务业绩将并入集团的财务报表。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421775.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药(01177)完成收购赫吉亚100%股权","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","BK1191","HK0000165453.HKD","BK1515","01177","BK1589","BK1521","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623902323","title":"中国生物制药(01177)3月30日耗资5842.4万港元回购1000万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623902323","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623902323?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:50","pubTimestamp":1774860636,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)公布，2026年3月30日耗资5842.4万港元回购1000万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药(01177)3月30日耗资5842.4万港元回购1000万股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","IE00BZ08YS42.EUR","BK1191","01177","BK1521","BK1589","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177768694","title":"中国生物制药：3月27日及3月30日合计回购1,535万股，涉资约8,986.17万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177768694","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177768694?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:47","pubTimestamp":1774860441,"startTime":"0","endTime":"0","summary":"中国生物制药于2026年3月30日公告称，于3月27日及3月30日先后在香港联交所场内购回合计15,350,000股普通股。其中，3月27日购回5,350,000股，约占当时已发行股本的0.029%，每股价格介乎港币5.85元至5.89元，总金额约3,143.77万港元；3月30日购回10,000,000股，约占当时已发行股本的0.053%，每股价格介乎港币5.81元至5.85元，总金额约5,842.40万港元。两次回购合计耗资约8,986.17万港元。本次回购依据2025年6月10日通过的购回授权进行，剩余可回购额度为1,876,071,723股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623901263","title":"里昂：降中国生物制药(01177)目标价至8.9港元 新产品发布和平台扩展撑下阶段增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2623901263","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623901263?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:00","pubTimestamp":1774857636,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，中国生物制药2025下半财年收入及盈利低于预期，收入同比增长10%，利润同比下跌40%。考虑到2025下半财年业绩疲软及商业发展收入贡献正常化，里昂将集团今明两年收入预测下调3%至5%，盈利预测下调11%至13%，并引入2028财年预测; 目标价由9.2港元下调至8.9港元，维持“跑赢大市”评级。里昂预测集团2026、2027及2028财年收入增长率分别为13%、14%及12%，并预期2027及2028财年净利润增长率分别为15%及13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623259367","title":"【券商聚焦】交银国际维持中国生物制药(01177)买入评级 指公司业务多线延伸 本土化MNC雏形初显","url":"https://stock-news.laohu8.com/highlight/detail?id=2623259367","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623259367?lang=zh_cn&edition=full","pubTime":"2026-03-30 10:57","pubTimestamp":1774839425,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，中国生物制药 2025年持续经营业务的收入同比增长10.3%，符合公司此前的指引。公司业务多线延伸，本土化MNC雏形初显。该机构基于2025年业绩表现下调公司2026-27年经调整净利润预测，以反映该机构对于BD合作收入确认节奏及存量仿制药收入更审慎的预期，下调DCF目标价至7.7港元，对应36倍/1.1倍2026年市盈率/PEG，维持买入评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977644","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623625303","title":"招银国际：维持中国生物制药(01177)“买入”评级 下调目标价至8.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623625303","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623625303?lang=zh_cn&edition=full","pubTime":"2026-03-30 09:52","pubTimestamp":1774835576,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，下调中国生物制药目标价7.4%，从9.4港元降至8.7港元，反映该行对非BD收入预期的下调，维持“买入”评级。中国生物制药2025年收入同比增10.3%至318.3亿元人民币(下同)，其中创新产品收入同比增26.2%至15.2亿元，占总收入的47.8% ；经调整归母净利同比增31.4%至45.4亿元，若剔除科兴中维的分红，经调整归母净利仍同比增长15%。随着仿制药营收企稳以及创新药销售持续发力，该行认为2026年公司业绩将持续稳健增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151385384","title":"中国生物制药3月27日回购535万股股份，耗资约3143.77万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1151385384","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151385384?lang=zh_cn&edition=full","pubTime":"2026-03-27 17:12","pubTimestamp":1774602760,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司于2026年3月27日发布公告，披露公司在香港联交所场内回购普通股535万股，占已发行股本约0.029%。回购价格区间为每股港币5.85元至5.89元，总耗资约3143.77万港元。公司表示，本次回购基于2025年6月10日获股东大会通过的购回授权，授权可回购的股份上限为1876071723股。公司确认已遵守香港联合交易所有限公司证券上市规则及相关法例规定。公告由公司秘书赖娟签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622331844","title":"中国生物制药(01177)3月27日斥资3143.8万港元回购535万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622331844","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622331844?lang=zh_cn&edition=full","pubTime":"2026-03-27 17:10","pubTimestamp":1774602634,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2026年3月27日斥资3143.8万港元回购535万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1521","BK1515","IE00BZ08YS42.EUR","HK0000165453.HKD","BK1589","BK1191","IE00BZ08YT58.USD","01177","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622486108","title":"花旗：中国生物制药(01177)去年盈利逊预期 目标价降至10港元 评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2622486108","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622486108?lang=zh_cn&edition=full","pubTime":"2026-03-27 14:42","pubTimestamp":1774593765,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，中国生物制药去年收入同比升10.3%至318亿元人民币，大致符合预期，但纯利同比升22%至23亿元人民币，低于市场及该行预期，盈利较低为无形资产减值及终止非核心业务和联营公司提供空间，未来增长奠下基础。该行将2026及27年收入预测分别上调3%及下调1%，每股盈利预测调低16%及18%，因预期少数股东权益上升，目标价由10.8港元下调至10港元，维持“买入”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622854774","title":"中国生物制药净利增长31.4%，创新药成产业升级核心引擎","url":"https://stock-news.laohu8.com/highlight/detail?id=2622854774","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622854774?lang=zh_cn&edition=full","pubTime":"2026-03-26 19:12","pubTimestamp":1774523520,"startTime":"0","endTime":"0","summary":"3月26日，在医药行业整体处于深度调整与结构重构的关键节点，中国生物制药（01177.HK）发布了财报，2025年该公司实现营收和净利润双位数增长。财报显示，2025年公司全年实现营收318.3亿元，同比增长10.3%，经调整Non-HKFRS归母净利润45.4亿元，同比增长31.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603263685746631.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685746631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BZ08YR35.GBP","BK1574","BK1589","01177","BK1521","HK0000165453.HKD","BK1515","IE00BZ08YS42.EUR","BK1191","159992","IE00BZ08YT58.USD","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622613830","title":"中国生物制药(01177)英文股份简称将更改为“SBP GROUP”","url":"https://stock-news.laohu8.com/highlight/detail?id=2622613830","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622613830?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:48","pubTimestamp":1774514892,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)公布， 于香港联合交易所有限公司买卖公司股份的英文股份简称将由“SINO BIOPHARM”更改为“SBP GROUP”，由2026年3月31日上午九时正起生效。公司中文股份简称保持不变，仍为“中国生物制药”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","01177","BK1191","HK0000165453.HKD","BK1521","IE00BZ08YT58.USD","BK1589","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196901070","title":"中国生物制药将于2026年7月20日派发末期股息每股0.05港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1196901070","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196901070?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:42","pubTimestamp":1774514563,"startTime":"0","endTime":"0","summary":"中国生物制药(01177)\n公告显示，公司董事会宣布派发二零二五年度末期股息，每股股息为0.05港元，财政年度截止日期为2025年12月31日。股东批准日期为2026年6月17日，股息除净日为2026年6月24日，股东如欲享有股息分派须于2026年6月25日16:30前办理过户手续。公司股份过户登记册将于2026年6月26日至2026年7月2日暂停登记，记录日期为2026年7月2日，预定股息派发日为2026年7月20日。\n据悉，此次股息性质为普通股息，过户登记处为卓佳证券登记有限公司，地址位于香港夏慤道16号远东金融中心17楼。公司董事会包括六位执行董事及五位独立非执行董事。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622830125","title":"中国生物制药：7月20日将派发股息0.05港元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622830125","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622830125?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:40","pubTimestamp":1774514400,"startTime":"0","endTime":"0","summary":"南财智讯3月26日电，中国生物制药（01177.HK）公告，公司2025年度末期股息为每股0.05港元，股息派发日为2026年7月20日；除净日为2026年6月24日，记录日期为2026年7月2日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685568527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","IE00BZ08YS42.EUR","BK1521","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","BK1191","01177","BK1515","HK0000165453.HKD","BK4585","BK1589","VIG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622378830","title":"中国生物制药(01177)发布年度业绩，归母盈利23.43亿元 同比减少33.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622378830","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622378830?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:39","pubTimestamp":1774514388,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布截至2025年12月31日止年度业绩，该集团取得收入人民币318.34亿元，同比增加10.25%;归属于母公司持有者的本年盈利人民币23.43亿元，同比减少33.04%;每股基本盈利人民币13.02分;拟派末期股息每股5港仙。2025年，集团创新产品收入达到人民币152.2亿元，同比增长26.2%。截至2025年12月31日止年度，研发总投入约人民币63.17亿元，占集团收入约19.8%，其中约92.9%已计入损益表中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1191","BK1589","IE00BZ08YT58.USD","01177","IE00BZ08YR35.GBP","BK1521","HK0000165453.HKD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622904231","title":"中国生物制药MSCIESG评级跃升至AA，进阶速度超行业平均水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2622904231","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622904231?lang=zh_cn&edition=full","pubTime":"2026-03-25 14:07","pubTimestamp":1774418821,"startTime":"0","endTime":"0","summary":"3月23日，国际权威指数机构MSCI发布最新环境、社会及治理评级结果。凭借在ESG领域的卓越实践，中国生物制药在2年时间里实现了从A级至AA级的跃迁突破，进阶速度远超行业平均水平。中国生物制药于2020年在港交所上市，自2017年起已连续十年自愿披露ESG报告，体现企业对长期可持续发展的重视。截至目前，中国生物制药旗下已有3家成员企业荣获国家级“绿色工厂”称号，绿色可持续发展实践获得广泛认可。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/25/20260325305933.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/25/20260325305933.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260325/32097012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621577153","title":"中国生物制药(01177)：MSCI ESG评级升至AA级","url":"https://stock-news.laohu8.com/highlight/detail?id=2621577153","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621577153?lang=zh_cn&edition=full","pubTime":"2026-03-23 17:30","pubTimestamp":1774258230,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，本集团凭借在环境、社会及管治领域的系统布局、持续深耕与卓越实践，Morgan Stanley Capital International  ESG评级由A级升至AA级，成为全球大型药企ESG实践的卓越领导者。此次评级升至AA级，代表MSCI对本集团ESG管理水平与实践成效的高度认可，是本集团践行可持续发展、履行企业社会责任的重要里程碑，更为中国创新医药企业高质量、可持续发展树立典范。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MSCI","ESG","01177","159717"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141927439","title":"财报前瞻｜中国生物制药本季度营收预测未披露，机构聚焦新品放量与费用效率","url":"https://stock-news.laohu8.com/highlight/detail?id=1141927439","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141927439?lang=zh_cn&edition=full","pubTime":"2026-03-19 10:32","pubTimestamp":1773887532,"startTime":"0","endTime":"0","summary":"中国生物制药将于2026年03月26日（盘后）发布最新季度财报，市场关注创新药放量、集采与医保谈判对盈利能力的影响以及费用与现金流改善节奏。上季度中国生物制药营收约为175.75亿，毛利率为82.47%，归属于母公司股东的净利润为16.94亿，净利率为19.28%，调整后每股收益未披露；公开口径未提供同比数据，故不在此展示同比增速。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜中国生物制药本季度营收预测未披露，机构聚焦新品放量与费用效率","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":0.0725},{"period":"1month","weight":0.0816},{"period":"3month","weight":0.0291},{"period":"6month","weight":-0.242},{"period":"1year","weight":0.6706},{"period":"ytd","weight":0.0291}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":-0.0294},{"period":"3month","weight":-0.0131},{"period":"6month","weight":-0.068},{"period":"1year","weight":0.0899},{"period":"ytd","weight":-0.0131}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.008254},{"month":2,"riseRate":0.652174,"avgChangeRate":0.056687},{"month":3,"riseRate":0.565217,"avgChangeRate":0.045006},{"month":4,"riseRate":0.521739,"avgChangeRate":0.028235},{"month":5,"riseRate":0.727273,"avgChangeRate":0.043347},{"month":6,"riseRate":0.363636,"avgChangeRate":0.00957},{"month":7,"riseRate":0.636364,"avgChangeRate":0.047691},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.010062},{"month":9,"riseRate":0.409091,"avgChangeRate":-0.015174},{"month":10,"riseRate":0.545455,"avgChangeRate":0.025184},{"month":11,"riseRate":0.5,"avgChangeRate":0.066781},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.01175}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SINO BIOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}